Drug Profile
Tramadol/type-5 cyclic nucleotide phosphodiesterase inhibitor - Aytu BioPharma
Alternative Names: PDE5 inhibitor/tramadol - Aytu BioPharma; Tramadol/PDE5 inhibitor - Aytu BioPharma; Type-5 cyclic nucleotide phosphodiesterase inhibitor/tramadol - Aytu BioPharma; Zertane-ED™; Zertane/PDE5 inhibitorLatest Information Update: 24 Mar 2021
Price :
$50
*
At a glance
- Originator Ampio Pharmaceuticals
- Developer Aytu BioPharma; Daewoong Pharmaceutical
- Class Cyclohexanols; Dimethylamines; Opioid analgesics; Small molecules
- Mechanism of Action Opioid mu receptor agonists; Serotonin uptake inhibitors; Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Erectile dysfunction; Premature ejaculation
Most Recent Events
- 22 Mar 2021 Neos Therapeutics has merged with Aytu BioScience to form Aytu BioPharma
- 16 Jul 2016 No recent reports of development identified for preclinical development in Erectile-dysfunction in South Korea (PO, Tablet)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Premature-ejaculation in South Korea (PO, Tablet)